Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
58 participants
OBSERVATIONAL
2025-12-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
NCT03000439
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
NCT01500551
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
NCT01904279
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
NCT00988221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tofacitinib
Patients affected by JIA and treated with tofacitinib
Tofacitinib
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tofacitinib
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.
Age under 18 years at the time of the treatment indication with tofacitinib.
Exclusion Criteria
Reactive arthritis
Arthritis associated with inflammatory bowel disease
Arthritis associated with another autoimmune disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Consorci Sanitari de l'Alt Penedès i Garraf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Sant Joan de Déu Barcelona
Barcelona, Barcelona, Spain
Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Hospital de Vilafranca
Vilafranca del Penedès, Barceona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSAPG-78
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.